ALNY vs. RGC: A Head-to-Head Stock Comparison

Updated on November 21, 2025

Here’s a clear look at ALNY and RGC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	ALNY	RGC
Company Name	Alnylam Pharmaceuticals, Inc.	Regencell Bioscience Holdings Limited
Country	United States	Hong Kong
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Pharmaceuticals
Market Capitalization	60.39 billion USD	6.35 billion USD
Exchange	NasdaqGS	NasdaqCM
Listing Date	June 1, 2004	July 16, 2021
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of ALNY and RGC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ALNY vs. RGC: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	ALNY	RGC
5-Day Price Return	1.69%	-8.89%
13-Week Price Return	0.06%	-3.96%
26-Week Price Return	68.31%	53.28%
52-Week Price Return	69.75%	7,311.76%
Month-to-Date Return	-1.51%	-24.32%
Year-to-Date Return	90.88%	9,592.31%
10-Day Avg. Volume	0.97M	0.13M
3-Month Avg. Volume	1.14M	0.32M
3-Month Volatility	30.24%	89.95%
Beta	0.30	2.34

Profitability

Return on Equity (TTM)

ALNY

-274.21%

Biotechnology Industry

Max: 96.19%
Q3: 12.45%
Median: -16.39%
Q1: -47.43%
Min: -131.19%

ALNY has a negative Return on Equity of -274.21%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

RGC

-54.75%

Pharmaceuticals Industry

Max: 38.95%
Q3: 20.34%
Median: 11.59%
Q1: 3.32%
Min: -10.91%

RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

ALNY vs. RGC: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

ALNY

-12.96%

Biotechnology Industry

Max: 84.13%
Q3: 19.34%
Median: -1.39%
Q1: -117.64%
Min: -296.77%

ALNY has a negative Net Profit Margin of -12.96%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

RGC

Pharmaceuticals Industry

Max: 39.07%
Q3: 19.28%
Median: 13.48%
Q1: 5.73%
Min: -8.86%

Net Profit Margin data for RGC is currently unavailable.

ALNY vs. RGC: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

ALNY

-7.32%

Biotechnology Industry

Max: 78.85%
Q3: 20.86%
Median: 0.51%
Q1: -128.29%
Min: -315.84%

ALNY has a negative Operating Profit Margin of -7.32%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

RGC

Pharmaceuticals Industry

Max: 45.58%
Q3: 24.35%
Median: 18.05%
Q1: 7.58%
Min: -11.88%

Operating Profit Margin data for RGC is currently unavailable.

ALNY vs. RGC: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Profitability at a Glance

Symbol	ALNY	RGC
Return on Equity (TTM)	-274.21%	-54.75%
Return on Assets (TTM)	-7.41%	-51.38%
Net Profit Margin (TTM)	-12.96%	--
Operating Profit Margin (TTM)	-7.32%	--
Gross Profit Margin (TTM)	83.64%	--

Financial Strength

Current Ratio (MRQ)

ALNY

2.80

Biotechnology Industry

Max: 15.83
Q3: 7.97
Median: 4.06
Q1: 2.64
Min: 0.72

ALNY’s Current Ratio of 2.80 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

RGC

42.68

Pharmaceuticals Industry

Max: 5.45
Q3: 2.99
Median: 1.98
Q1: 1.29
Min: 0.78

RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

ALNY vs. RGC: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ALNY

4.10

Biotechnology Industry

Max: 1.27
Q3: 0.62
Median: 0.13
Q1: 0.00
Min: 0.00

With a Debt-to-Equity Ratio of 4.10, ALNY operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

RGC

0.00

Pharmaceuticals Industry

Max: 1.79
Q3: 0.78
Median: 0.31
Q1: 0.08
Min: 0.00

Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

ALNY vs. RGC: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

ALNY

-0.95

Biotechnology Industry

Max: 72.37
Q3: 1.71
Median: -15.18
Q1: -65.75
Min: -166.46

ALNY has a negative Interest Coverage Ratio of -0.95. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

RGC

Pharmaceuticals Industry

Max: 103.95
Q3: 43.60
Median: 10.15
Q1: 2.37
Min: -42.71

Interest Coverage Ratio data for RGC is currently unavailable.

ALNY vs. RGC: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

Symbol	ALNY	RGC
Current Ratio (MRQ)	2.80	42.68
Quick Ratio (MRQ)	2.63	41.89
Debt-to-Equity Ratio (MRQ)	4.10	0.00
Interest Coverage Ratio (TTM)	-0.95	--

Growth

Revenue Growth

ALNY vs. RGC: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ALNY vs. RGC: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ALNY

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ALNY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

RGC

0.00%

Pharmaceuticals Industry

Max: 6.72%
Q3: 3.48%
Median: 1.90%
Q1: 0.00%
Min: 0.00%

RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ALNY vs. RGC: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

ALNY

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ALNY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

RGC

0.00%

Pharmaceuticals Industry

Max: 199.58%
Q3: 85.87%
Median: 49.36%
Q1: 1.12%
Min: 0.00%

RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ALNY vs. RGC: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Dividend at a Glance

Symbol	ALNY	RGC
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

ALNY

Biotechnology Industry

Max: 115.91
Q3: 56.76
Median: 21.80
Q1: 15.79
Min: 4.51

P/E Ratio data for ALNY is currently unavailable.

RGC

Pharmaceuticals Industry

Max: 52.64
Q3: 29.89
Median: 20.77
Q1: 13.37
Min: 5.71

P/E Ratio data for RGC is currently unavailable.

ALNY vs. RGC: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

ALNY

24.10

Biotechnology Industry

Max: 58.56
Q3: 29.31
Median: 8.30
Q1: 4.89
Min: 0.86

ALNY’s P/S Ratio of 24.10 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

RGC

Pharmaceuticals Industry

Max: 8.74
Q3: 4.66
Median: 2.37
Q1: 1.67
Min: 0.11

P/S Ratio data for RGC is currently unavailable.

ALNY vs. RGC: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

ALNY

169.67

Biotechnology Industry

Max: 17.92
Q3: 10.38
Median: 4.78
Q1: 2.85
Min: 0.78

At 169.67, ALNY’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

RGC

9.57

Pharmaceuticals Industry

Max: 9.86
Q3: 5.28
Median: 2.48
Q1: 1.57
Min: 0.59

RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

ALNY vs. RGC: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Pharmaceuticals industry benchmarks.

Valuation at a Glance

Symbol	ALNY	RGC
Price-to-Earnings Ratio (TTM)	--	--
Price-to-Sales Ratio (TTM)	24.10	--
Price-to-Book Ratio (MRQ)	169.67	9.57
Price-to-Free Cash Flow Ratio (TTM)	331.60	--